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Background: Kan Jang® oral solution (KJ) is a ﬁxed combination of aqueous ethanolic extracts of Justicia
adhatoda L. leaf, Echinacea purpurea (L.) Moench root, and Eleutherococcus senticosus (Rupr. & Maxim.) Harms
root. It is approved in Scandinavia as an herbal medicinal product for respiratory tract infection treatment.
Purpose: The present clinical trial aimed to compare the antitussive effect of KJ with placebo (PL) and
bromhexine (BH) among patients of 18–65 years old with non-complicated upper respiratory infections (URI;
i.e., common cold).
Study design: We performed a parallel-group, randomized, double-blinded, placebo-controlled trial in in 177
patients with acute URI over a 5 day period.
Methods: We investigated the antitussive effects of a KJ (30 ml/day; 762 mg genuine extracts with stan-
dardized contents of 0.2 mg/ml vasicine, 0.8 mg/ml chicoric acid, and 0.03 mg/ml eleutherosides B and E),
bromhexine hydrochloride (24mg/30ml/day) and PL on cough and bloodmarkers. The primary outcomewas
cough relief, which was assessed as the change of cough frequency from baseline (cough index). Secondary
outcomes were safety with regards to reported adverse events (AEs) and hematological data.
Results: Both KJ and BH relieved cough more effectively than placebo. On the third and fourth days of treat-
ment, we observed faster improvement in the group receiving KJ compared to in the groups receiving BH
(100%) or PL (100%), indicating a slightly shorter recovery time in the KJ group. KJ showed a good tolerability
and safety proﬁle.
Conclusion: KJ exerted signiﬁcant antitussive effects in URI. The present data further support the therapeutic
use of KJ in upper respiratory tract infections.
© 2015 The Authors. Published by Elsevier GmbH.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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An acute upper respiratory infection (URI) can affect the nose, si-
uses, pharynx, larynx, and/or bronchi. Common URI symptoms in-
lude cough associated with serous or mucoid sputum (tracheitis,
ronchitis); runny nose, sniﬄing, and nasal congestion (rhinitis);
oarseness (laryngitis); diﬃculty swallowing and a sore, scratchy,
nd phlegmy throat (pharyngitis and tonsillitis); sore muscles and
eneral malaise; headache; and tiredness (Gwaltney, 2000). When
asal cells are infected by a cold virus, inﬂammatory mediators are
eleased, stimulating nociceptors (pain nerve ﬁbers) and activatingAbbreviations: KJ, Kan Jang ® oral solution; PL, placebo; BH, bromhexine.
∗ Corresponding author. Tel.: +37494 28 20 18.
E-mail address: areg@armnado.am (A. Hovhannisyan).
s
p
ttp://dx.doi.org/10.1016/j.phymed.2015.10.001
944-7113/© 2015 The Authors. Published by Elsevier GmbH. This is an open access article unneeze and cough reﬂexes (Gwaltney and Ruckert, 1997). URIs are
sually self-limiting, and thus treatments focus on reducing symp-
om duration and intensity, maximizing patient comfort, and limiting
omplications. Cough due to URI is a frequent and disruptive symp-
om. Only limited evidence supports the few therapeutic agents avail-
ble to treat acute URI-related cough (Paul, 2012). Common cough
reatments include narcotic antitussives, such as codeine and dex-
romethorphan. Cough suppressants act on the brain to depress the
ough reﬂex center (Reisine and Pasternak, 1996), and might be use-
ul in some instances, but their eﬃcacy is not fully proven when ex-
ectoration is required (Heinrich et al., 2004).
Preclinical studies show that J. adhatoda extracts have antitus-
ive (Sarkar et al., 2014; Nosalova et al., 2013; Dhuley, 1999), ex-
ectorant (Gibbs, 2009; Sharafkhaneh et al., 2007; Soni et al., 2008;der the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tGrange and Snell, 1996), mucolytic (Gibbs, 2009; Sharafkhaneh et al.,
2007; Grange and Snell, 1996), antibacterial (Bose and Chatterjee,
2015; Zulqarnain et al., 2015; Singh and Sharma, 2013; Jha et al.,
2012; Shahwar et al., 2012; Jayashankar et al., 2011; Ignacimuthu
and Shanmugam, 2010; Gupta et al., 2010), and anti-inﬂammatory
(Singh and Sharma, 2013; Nosalova et al., 2013; Chakraborty and
Brantner, 2001; Sharafkhaneh et al., 2007) effects. Several studies
describe the antitussive and respiratory effects of alkaloid vasicine
and its oxidation product vasicinone isolated from Justicia adhatoda
L. leaves (Amin and Mehta, 1959; Cambridge et al., 1962; Mehta
et al., 1963; Bhide et al., 1974, 1976; Liu et al., 2015). Both in vitro and
in vivo studies show bronchodilatatory activity of vasicine at doses of
2.5–10 mg/kg, which increases with the combination of vasicine and
vasicinone. Vasicine reportedly shows the greatest activity against
histamine-induced bronchospasm (Cambridge et al., 1962), increases
ciliarymovements, and inhibits bronchialmucus secretion by 40–50%
(Gupta et al., 1977). Thus, the cough relief effects of Justicia adhatoda
L. extract are mainly associated with the bronchodilation and mu-
colytic effects of vasicine. However, the extract’s antitussive activity
(Dhuley, 1999) is due to some other active constituents (Gupta et al.,
1977). In animal studies, Justicia adhatoda L. extract shows 1/20–1/40
the antitussive activity of codeine with intravenous administration in
mechanically and electrically induced coughing, and antitussive ac-
tivity similar to codeinewith oral administration in coughing induced
by irritant aerosols (Dhuley, 1999).
In vitro and in vivo experiments also show that Echinacea pur-
purea (L.) Moench, and Eleutherococcus senticosus (Rupr. & Maxim.)
extracts activate immune system-stimulating cell defense mecha-
nisms against viral and microbial infections (Echinaceae Purpureae
Radix, 2009; Eleutherococci Radix, 2009). Moreover, E. senticosus in-
duces nonspeciﬁc resistance through adaptogenic effects that can ac-
celerate recovery processes during convalescence (Radix Eleuthero-
cocci, 2002).
The concepts of multi-target therapy and synergy suggest these
three herbal drugs could be combined to produce a more effective
and safe treatment, as has been demonstrated with numerous medi-
cal treatments (Williamson, 2001;Wagner, 2006;Wagner and Ulrich-
Merzenich, 2009; Efferth and Koch, 2011). However, synergistic in-
teractions of multiple constituents can be accompanied by many
antagonistic and undesirable interactions (Panossian et al., 2013).
Therefore, clinical studies are needed to conﬁrm the eﬃcacy and
safety of new combinations.
Kan Jang® oral solution (KJ) is a ﬁxed combination of aqueous
ethanolic extracts of Justicia adhatoda L. leaf, Echinacea purpurea (L.)
Moench root, and Eleutherococcus senticosus (Rupr. & Maxim.) Harms
root, which is approved in Scandinavia as an herbal medicinal prod-
uct for URI treatment. A clinical study demonstrated the eﬃcacy of
KJ (30 ml taken 3 times daily for 6 days) for relief of inﬂammatory
symptoms (e.g., throat irritability, cough severity, eﬃcacy of mucus
discharge in the respiratory tract, nasal congestion, and general feel-
ings of sickness) among patients with acute URIs (Narimanian et al.,
2005). That study included three arms — KJ, the combination of Echi-
nacea purpurea and Eleutherococcus senticosus, and the positive active
control bromhexine hydrochloride — without a placebo group. Thus,
there remains a need to test the antitussive potential and safety of KJ
compared with placebo.
The present study aimed to evaluate the eﬃcacy and tolerability
of KJ compared to placebo and the active control bromhexine, with
regard to its antitussive effect in patients with non-complicated URIs.
Materials and methods
Study design
We designed a randomized, placebo-controlled, three-arm
parallel-group, double-blind phase II trial to investigate the eﬃcacy ofJ compared to that of bromhexine (BH; positive control) and placebo
PL; negative control). The study enrolled patients from the Yere-
an State Medical Centre of Armenia who presented acute uncompli-
ated URIs involving cough (ICD-10 codes J00–J06) between Novem-
er 2012 and August 2014. Inclusion criteria were age of 18–65 years
nd predominant complaint of the ﬁrst signs and symptoms of un-
omplicated URI (e.g., sore throat, blocked nose, runny nose, hoarse-
ess, cough, headache, and general malaise). Patients were excluded
f they had a known history of allergies to cut ﬂowers, herbs, or bit-
er substances; had acute symptoms for over 36 hours or fever of
38.5 °C; were taking antibiotics, anti-inﬂammatory drugs, or anti-
istamine; or were pregnant or breast-feeding. Of the 180 patients
ecruited, 177 were included in the study.
All included patients gave their written informed consent. The
tudy protocols were approved by the Health Research Ethics Board
t the Yerevan Medical State University of Armenia (Protocol no. 01-
011-10-13). All patients monitoring was in compliance with the re-
ised declaration of Helsinki.
ubject withdrawals
Patients were free to withdraw from the study at any time. More-
ver, subjects were asked to withdraw from the study if they de-
eloped an allergy or hypersensitivity to the study medication, de-
eloped serious side-effects, showed abnormal clinical biochemistry
alues, or did not comply with the study protocol. No patients with-
rew from the study.
ntervention and control treatments
The KJ solution contained 9 mg/ml genuine extract (in 55%
thanol) from 23–63mg dried root of Echinacea purpurea (L.) Moench
adix (purple coneﬂower), 14 mg/ml genuine extract (in water) from
9–70 mg dried leaves of Justicia adhatoda L. folium (Malabar nut),
nd 2 mg/ml genuine extract (in 70% ethanol) from 34–60 mg
ried root of Eleutherococcus senticosus (Rupr. & Maxim.) Maxim.
adix (Siberian ginseng). The solution base comprised sorbitol, hus-
enkräuter aroma, ginger extract, peppermint oil, dark syrup, ben-
oate, and water. The preparation was standardized for contents of
asicine (0.2 mg/ml), chicoric acid (0.8 mg/ml), and eleutherosides B
nd E (0.03 mg/ml). Validated HPLC methods were used to evaluate
electivity, accuracy, and precision (RSD < 5%) (Supplementary Fig.
). KJ was manufactured following GMP and released by the Swedish
erbal Institute Research & Development, Vallberga, Sweden (Batch
o. 2733).
The active control was the standard over-the-counter medica-
ion bromhexine hydrochloride (Batch no. 116075; Boehringer Ingel-
eim) at a concentration of 1.6 mg/ml. This BH was dissolved in a
iquid matrix containing the same excipients as the Kan Jang oral
olution: sorbitol, hustenkräuter aroma, ginger extract, peppermint
il, dark syrup, benzoate, and water. The ﬁnal BH concentration was
.8 mg/ml (Batch no. 50136). The placebo was a mixture of sorbitol,
ustenkräuter aroma, ginger extract, peppermint oil, dark syrup, ben-
oate, and water (Batch no. 50135). Reference samples were stored at
he QC laboratory of the Swedish Herbal Institute.
llocation and blinding
Participants each received a labeled paper box containing either
J, bromhexine, or placebo in a dark glass 300 ml bottle with a cap,
ealing ring, and a measuring dosage cup (graduated at 5, 10, 15, 20,
nd 30 ml). KJ, BH, and PL preparations all had a similar appearance,
est, smell, color, test, and viscosity and were organoleptically undis-
inguishable. The trial subjects were blinded to their treatment since
he labeled bottles contained solutions of identical appearance.
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Table 1
Demographic characteristics and baseline of frequency of cough of patients entered the study,
n = 177.
Mean ± SD P value
KJ PL BH
Number of patients 66 54 57 KJ vs. PL KJ vs. BH
Males/Females 30/36 25/29 21/36 >0.05 >0.05
Age 34.8 ± 11.39 31.9 ± 11.57 32.1 ± 10.38 >0.05 >0.05
Cough frequency 5.30 ± 0.07 5.04 ± 0.09 5.12 ± 0.08 >0.05 >0.05
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tTo ensure that the study was double-blind, the study investigators
ere also blinded to the treatment type using the following proce-
ures. Prior to the study, a treatment randomization code was gener-
ted at the factory, which contained information about the contents
f each bottle, e.g., encoding KJ, BH, or PL. This code was generated
sing the Excel Random Number Generator, with a table containing
hree columns (A, B, and C) that was ﬁlled with randomly distributed
nique numbers from 1 to 198. KJ, PL, and BHwere assigned to sets of
ottles A, B, and C at the manufacturing site. The treatment random-
zation code was kept by a qualiﬁed pharmacist (QP) at the investiga-
ional product manufacturing site, and was provided to the Principal
nvestigator when all patients completed the treatment.
Participants were enrolled by the principal investigator in collab-
ration with study doctors. The study monitor assigned patients to
tudy groups A, B, and C. The study monitor did not receive the ran-
omization code until the end of the study. The Principal Investiga-
or generated the Study Participants list, identifying the patients and
he study supplement packages (treatment numbers). At the end of
he study, statistical analyses were performed using the Study Partic-
pants list to compare the data obtained in groups A, B, and C. Fol-
owing these statistical analyses, the QP broke the code providing the
ctual assignments of groups A, B, and C.
atient intervention and examinations
At visit 1 (Supplementary Fig. 2), patients underwent a routine
edical examination that included physical examinations (anamne-
is collection, detailed chest auscultation and percussion, and ther-
ometry) and laboratory blood hematological tests. During this ini-
ial examination, the doctor counted the cough frequency (number
f coughing bouts within 30 min), recorded the results in the Case
eport Form (CRF), and instructed patents in how self-assess their
ough frequency at home. Each participant was provided a report
orm, and was instructed to count the number of coughing bouts for
0 min following the ﬁrst coughing incident in the morning immedi-
tely after waking up.
Patients who passed their initial examination and gave informed
onsent to participate were then assigned to a randomized study
edication. They were provided this medication and asked to take
0 ml of oral solution per day for the next 5 days. The medication
as to be taken 30 min after eating breakfast. The patients were also
nstructed to regularly record the degree of their clinical symptoms
nd the amount of medication taken daily on a patient’s-self assess-
ent forms. At the end of the study (visit 2, day 5), the patients again
et with a doctor. At this visit, the doctor checked compliance (liquid
onsumption) and checked and signed the patient’s completed forms.
utcomes
The primary outcome was eﬃcacy of treatment (Cough Relief In-
ex), which was determined based on the difference between the
ough frequency on day 1 (baseline, determined by the physician at
isit 1) and on each successive day of treatment (determined by the
atient at home). Cough frequency (the number of coughing bouts in0 min) was expressed using a ﬁxed scale from 0 to 9, where 0 indi-
ated no cough, 1–3 a mild cough, 4–6 a moderate cough, and 7–9 a
evere cough. The mean cough frequency value at baseline was 5.0–
.3, indicating a moderate cough (Table 1). Patients were instructed
o immediately contact the investigator should they experience any
tudy events, deﬁned as any relevant event experienced by the pa-
ient during the study. Given examples included adverse effects and
nter-current illness. In the event of any allergic reactions, such as
kin rash, the medication would be stopped.
In addition to study events, safety was monitored using hemato-
ogical data. Laboratory blood analyses were performed using sam-
les from day 1 and day 5. Analyses included hemoglobin, red blood
ell count (RBC), color index, neutrophil count, basophil count, eosin
lates, and white blood cells (WBC), and were performed using an
utomated Hematology Analyzer pocH-100i (Sysmex Corporation,
obe, Japan).
ample size considerations
The sample size for the present study was calculated based on an
ffect size of 1.42 from a comparable study of KJ in URIs, in which
ough and other inﬂammatory symptoms were used as eﬃcacy out-
ome measures (Narimanian et al., 2005). Using a two sided, two-
ample t-test, it was calculated that 30 participants in each group
ere required to detect an absolute mean difference of 1.42 on the
ough relief score between the KJ and BH groups with 95% power at
0.05 level of signiﬁcance (Stat-Mate, version 2.00, 2004; GraphPad
oftware, Inc.). We prepared for a 20% drop-out rate, increasing our
ntended sample size to 118 participants (36 in each group). In the
ompleted trial, we had over 99% power to detect a between-means
ifference of 0.28 with a two-tailed alpha of 0.05: KJ, n = 66, SD =
.43; BH, n = 57, SD = 0.40; and PL, n = 54, SD = 0.28.
tatistical analysis
At each visit, data were recorded using a standardized assess-
ent method, and recorded in an Excel database that was used for
urther data management and statistical analyses (Evererett, 1989).
raphPad Prism software version 3.03 for Windows (San Diego, CA,
SA) was used for statistical analyses and graph generation. The pri-
ary analysis followed intention-to-treat principles. Statistical anal-
ses were performed using “observed” data, and involved evaluating
he patient’s change in scores from the initial visit (baseline) to later
ays of the study and the ﬁnal visit. All statistical tests were two-
ided, with a 0.05 level of signiﬁcance.
Before within-group or between-group comparisons, all data
ere checked for normality, with a cut-off value of 0.05. Based on
he normality test results, comparative assessment of the baseline
haracteristics between groups (KJ vs. PL and BH) was performed us-
ng either the Kruskal–Wallis non-parametric one-way ANOVA rank-
rder test, with post-hoc Dunn’s Multiple Comparison Test or the
arametric one-way independent measures ANOVA with Dunnett’s
ultiple Comparison Test. Changes within treatment groups over the
ourse of the study (before vs. after) were analyzed using the paired
-test for parametric data (variables with normal distribution) and
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Table 2
Baseline cough frequency scores at the beginning (day 1) and
the end (day 5) of the study.
Baseline score Day 5 score
Score KJ PL BH Score KJ PL BH
7 3 0 0 4 2 4 0
6 26 20 26 3 3 9 4
5 70 65 60 2 29 31 40
4 2 13 14 1 65 48 44
3 0 2 0 0 2 7 12
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pthe Wilcoxon signed-rank test or the Friedman test for several re-
peatedmeasures for non-parametric data. To assess the eﬃcacy of the
study supplements, we compared the mean changes from baseline
for each patient and each group (KJ vs. PL and BH) using the Kruskal–
Wallis non-parametric one-way ANOVA rank-order test, with post-
hocDunn’sMultiple Comparison Test, and/or the parametric one-way
independent measures ANOVA with Dunnett’s Multiple Comparison
Test (for variables with normal distribution).
Results
Study participants and baseline variables
A total of 180 subjects were recruited and 177 patients were in-
cluded in this study. These patients were randomly divided into three
groups. Participants ﬂow is outlined in Supplementary Fig. 3. Table 1
presents the baseline demographic and clinical characteristics of each
group and the relevant baseline data. The groups did not signiﬁcantly
differ in baseline demographics or other parameters (Table 1).
Treatment eﬃcacy
Over the course of the study, each group showed signiﬁcant relief
of cough compared to the baseline and/or each previous day (Tables 2
and 3).
Cough relief was measured as the change of the cough index from
baseline. On the third and fourth days of treatment, we found a signif-
icantly greater cough relief effect with KJ treatment compared to PL
and BH (Table 4, Supplementary Fig. 4). On the third treatment day,
the cough relief effect was 1.97 ± 0.021 in the KJ group, compared
to 1.759 ± 0.079 in the placebo group (P < 0.05) and 1.772 ± 0.083
in the BH group (P < 0.05). The difference in effect and the statisti-
cal signiﬁcance of the difference between the KJ and BH groups was
maximal on day 4 (P < 0.01). At the end of treatment (day 5), all pa-
tients had recovered, and the cough relief effects were similar in the
KJ and BH groups (P > 0.05). Our data also showed a greater speed
of recovery (assessed as cough relief effect) for patients in the KJ and
positive control groups compared to in the placebo group.Table 3
Cough frequency in the course of the study and cough relief (C
comparison.
K
n
m
Baseline, Day 1 5
Day 2 4
Day 3 3
Day 4 2
Day 5 1
Cough index on the day 5: change from baseline, P value 3
<
∗The intensity of cough measured as a cough index between groafety
The treatment was well tolerated. No serious adverse events were
bserved. Over the 5 day study period, a total of 12 minor adverse
vents were observed in 12 patients: 4 in the PL group (7.4%), 2 in
he KJ group (3.9%), and 6 in the BH group (10.5%). Minor adverse
vents included pruritus, diarrhea, abdominal pain, and skin rash. The
roportion of patients reporting adverse events did not signiﬁcantly
iffer between groups, and these events were not considered to be
reatment-related.
ematological and immunological parameters
The only statistically signiﬁcant between-group difference at the
nd of the study (day 5) was that lymphocyte count differed between
he BH and KJ groups (Table 5).
iscussion
Kan Jang® is a brand of herbal medicinal products that are used in
candinavia to treat URIs. Previous trials of drugs in various stages of
evelopment have investigated formulations containing Herba Adro-
raphidis extract, including a monodrug (Hancke et al., 1995; Cac-
res et al., 1997) and ﬁxed combinations of Herba Andrographidis
xtract with Radix Eleutherococci (Melchior et al., 2000; Gabrielian
t al., 2002; Kulichenko et al., 2003; Poolsup et al., 2004; Kligler
t al., 2006) or Radix Echinacea extracts (Spasov et al.,2004). Herbal
ablets or capsules with standardized andrographolide content are
ainly indicated for early prevention and relief of the symptoms of
RIs.
Another group of Kan Jang formulations includes ﬁxed combina-
ions of Folia Adhatoda extracts with extracts of Radix Eleutherococci
nd E. pallida (Thom and Wollan, 1997) or E. purpurea (Narimanian
t al., 2005). Oral solutions of these ﬁxed combinations are indicated
or cough relief, with the eﬃcacy presumably due to the antitus-
ive, bronchodilating, and expectorant effects of the alkaloid vasicine
Amin and Mehta, 1959; Cambridge et al., 1962; Mehta et al., 1963;
hide et al., 1974, 1976; Liu et al., 2015), which is an active constituent
f J. adhatoda leaf extract. Its semi-synthetic derivative bromhexine
Bisolvon) (Grange and Snell, 1996) is widely used as an over-the-
ounter mucolytic medication to reduce cough (Parvez et al., 1996),
articularly as an adjunct to antibiotics for acute pneumonia in chil-
ren and adults (Chang et al., 2014).
The present clinical trial investigated the antitussive effect of a
an Jang® oral solution containing a ﬁxed combination of aqueous
nd ethanolic extracts of Justicia adhatoda L. leaf, Echinacea purpurea
L.) Moench root, and Eleutherococcus senticosus (Rupr. & Maxim.)
arms root extracts (KJ). Our randomized double-blind three-arm
tudy aimed to compare the eﬃcacy and tolerability of KJ with a
lacebo andwith the active control BHwith respect to the antitussiveough index) at the end of the treatment: within group
J PL BH
= 66 n = 54 n = 57
ean ± SD mean ± SD mean ± SD
.303 ± 0.554 5.037 ± 0.643 5.140 ± 0.666
.333 ± 0.591 4.111 ± 0.691 4.281 ± 0.726
.333 ± 0.591 3.278 ± 0.787 3.368 ± 0.858
.364 ± 0.598 2.463 ± 0.884 2.526 ± 0.966
.379 ± 0.651 1.537 ± 0.905 1.351 ± 0.744
.924 ± 0.1052 3.500 ± 0.1511 3.772 ± 0.1290
0.0001 <0.0001 <0.0001
ups did not show any signiﬁcant difference at the start.
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Table 4
Eﬃcacy of treatment of the frequency of cough: cough index (cough relief effect form the baseline, day 1) in treatment
groups in the course of the treatment: between groups comparison.
KJ PL BH KJ vs. PL KJ vs. BH
n = 66 n = 54 n = 57 P value and summary P value and summary
mean ± SD mean ± SD mean ± SD
Day 2 0.970 ± 0.173 0.926 ± 0.381 0.860 ± 0.398 >0.05ns >0.05ns
Day 3 1.97 ± 0.172 1.759 ± 0.581 1.772 ± 0.627 <0.05∗ <0.05∗
Day 4 2.939± 0.241 2.574 ± 0.716 2.614 ± 0.773 <0.01∗∗ <0.01∗∗
Day 5 3.924 ± 0.404 3.500 ± 0.795 3.772 ± 0.567 <0.001∗∗∗ >0.05ns
Table 5
Inter-groups comparison of hematological/immunological parameters.
KJ PL BH KJ vs. PL KJ vs. BH
n = 66 n = 54 n = 57 P value P value
mean ± SD mean ± SD mean ± SD
Hemoglobin, (g/l) [Norm – 120–160 g/l]
Baseline 127.1 ± 13.31 128.2 ± 13.06 124.3 ± 14.61 >0.05 >0.05
Day 5 126.4 ± 13.23 127.6 ± 12.88 123.7 ± 14.34 >0.05 >0.05
Change from baseline 0.677 ± 2.310 0.531 ± 2.496 0.568 ± 2.711 >0.05 >0.05
RBC, (10∗12/l) [Norm – 3.5–5.0 1012/l]
Baseline 3.718 ± 0.387 3.752 ± 0.367 3.626 ± 0.423 >0.05 >0.05
Day 5 3.644 ± 0.366 3.687 ± 0.338 3.567 ± 0.408 >0.05 >0.05
Change from baseline 0.074 ± 0.065 0.065 ± 0.068 0.060 ± 0.078 >0.05 >0.05
Color Index, [Norm – 0.85–1.05]
Baseline 0.942 ± 0.049 0.943 ± 0.05 0.939 ± 0.049 >0.05 >0.05
Day 5 0.945 ± 0.050 0.946 ± 0.05 0.940 ± 0.049 >0.05 >0.05
Change from baseline −0.003 ± 0.009 −0.004 ± 0.01 −0.002 ± 0.009 >0.05 >0.05
Neutrophils, % [Norm – 1–6%]
Baseline 3.045 ± 1.513 3.037 ± 1.479 3.228 ± 1.476 >0.05 >0.05
Day 5 2.530 ± 1.14 2.519 ± 1.285 2.649 ± 1.275 >0.05 >0.05
Change from baseline 0.561 ± 0.096 0.518± 0.267 0.579 ± 0.258 >0.05 >0.05
Basophils, % [Norm – 47–72%]
Baseline 64.08 ± 4.368 64.09 ± 4.127 63.79 ± 3.261 >0.05 >0.05
Day 5 62.97 ± 4.325 62.70 ± 3.451 62.74 ± 2.955 >0.05 >0.05
Change from baseline 1.106 ± 0.785 1.389 ± 0.732 1.053 ± 0.583 >0.05 >0.05
Eosinophils, % [Norm – 0.5–5.0%]
Baseline. 3.515 ± 0.662 3.426 ± 0.716 3.614 ± 0.675 >0.05 >0.05
Day 5 2.955 ± 0.409 2.870 ± 0.516 2.930 ± 0.495 >0.05 >0.05
Change from baseline 0.5606 ± 0.096 0.556 ± 0.120 0.684 ± 0.110 >0.05 >0.05
Lymphocytes, %, [Norm –19–37%]
Baseline 24.24 ± 4.581 25.22 ± 4.756 24.21 ± 5.460 >0.05 >0.05
Day 5 23.38 ± 4.205 23.37 ± 5.275 23.21 ± 5.02 >0.05 >0.05
Change from baseline 0.864 ± 0.765 1.852 ± 0.967 1.000 ± 0.982 >0.05 >0.05
Monocytes, % [Norm – 2.9–11 %]
Baseline 3.045 ± 0.325 2.963 ± 0.433 2.947 ± 0.440 >0.05 >0.05
Day 5 3.000 ± 0.248 2.907 ± 0.293 2.930 ± 0.258 >0.05 >0.05
Change from baseline 0.045 ± 0.050 0.055 ± 0.071 0.017 ± 0.067 >0.05 >0.05
Erythrocytes sedimentation rate (ESR). mm/h [Norm – 2–20 mm/h]
Baseline 20.74 ± 4.531 19.26 ± 4.639 19.98 ± 4.725 >0.05 >0.05
Day 5 19.21 ± 4.219 17.33 ± 4.421 16.12 ± 4.886 >0.05 >0.05
Change from baseline 1.530 ± 0.762 1.926 ± 0.872 2.140 ± 0.9 >0.05 >0.05
Whyte blood cells, WBC (10∗9/L) [Norm –4–9.0 109/l]
Baseline 8.524 ± 0.581 8.287 ± 0.673 8.287 ± 0.759 >0.05 >0.05
Day 5 8.232 ± 0.612 8.023 ± 0.640 8.023 ± 0.696 >0.05 < 0.05∗
Change from baseline 0.292 ± 0.104 0.264 ± 0.127 0.264 ± 0.128 >0.05 >0.05
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pffect. The eﬃcacywas analyzed based on patient self-evaluations us-
ng a standard rating scale from 0–9 to indicate cough frequency and
ntensity.
The three treatment groups did not signiﬁcantly differ at base-
ine or at the end of treatment when all patients were almost
ully recovered. On the second day of treatment, we observed
igniﬁcant improvement and antitussive effect in all treatment
roups (including placebo), which gradually increased over the fol-
owing days. On the third and fourth days of treatment, the KJroup showed a greater reduction of cough intensity compared
o both the PL and BH groups, indicating a quicker recovery in
he KJ group. All treatments were well tolerated, with no seri-
us adverse events, and only 12 minor adverse events, including
ild pruritus in 6 patients (2 in each group). Overall, our data
howed that KJ exerted signiﬁcantly more rapid antitussive effects
n acute upper respiratory tract infections compared to both BH and
lacebo. Moreover, KJ showed good tolerability and a good safety
roﬁle.
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ZConclusion
Kan Jang® oral solution exhibits signiﬁcant antitussive effects
in acute upper respiratory tract infections. It has good tolerability
proﬁle.
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